The transforming growth factor b1 (TGFbl) signaling pathway is clinically very important. It is directly implicated in several birth defects, including Marfan Syndrome, Hereditary Hemorrhagic Telangiectasia (HHT), Camurati-Engelmann disease and cleft palate, as well as being involved in the etiology of the two most important multifactorial diseases affecting humans, namely cancer and cardiovascular (CV) disease. TGFbl is also a key regulator of immunomodulation. Genes encoding components of the TGFbl signaling pathway including TGFB1 have been shown to be functionally polymorphic in humans, and genetic associations have been found between carriers of specific TGFB1 polymorphic variants and disease susceptibility for cancer, atherosclerosis, myocardial infarction (Ml), hypertension and other cardiovascular diseases. The goal of this research is to identify and characterize the differential functions of genetic variants that influence the activity of TGFbl action in vivo, particularly with respect to angiogenesis and CV disease. The specific objective of this proposal is to characterize variants responsible for genetic modification within the TgfbmS locus on mouse chromosome 12 and to determine their role in vascular biology, and the role of orthologous genes at 2p25.1 in risk for Ml in humans. This information:a)Will increase our understanding of molecular pathways involved in TGFbl-mediated vascular remodeling, b) May provide screening tools for assessment of disease risk in ailments known to have a TGFB1 associationc) Will provide targets for prophylactic drug development of such diseases d) May provide predictive markers for response to anti-TGFb drug therapies

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-CICS (01))
Program Officer
Kindzelski, Andrei L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Arnold, Thomas D; Niaudet, Colin; Pang, Mei-Fong et al. (2014) Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking ?V?8-TGF? signaling in the brain. Development 141:4489-99
Kawasaki, Kyoko; Freimuth, Julia; Meyer, Dominique S et al. (2014) Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans. Proc Natl Acad Sci U S A 111:7723-8
Benzinou, Michael; Clermont, Frederic F; Letteboer, Tom G W et al. (2012) Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun 3:616
Lamouille, Samy; Connolly, Erin; Smyth, James W et al. (2012) TGF-?-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 125:1259-73
Freimuth, Julia; Clermont, Frederic F; Huang, Xiaozhu et al. (2012) Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc Natl Acad Sci U S A 109:18042-7
Akhurst, Rosemary J; Hata, Akiko (2012) Targeting the TGF? signalling pathway in disease. Nat Rev Drug Discov 11:790-811
Akhurst, Rosemary J (2012) The paradoxical TGF-? vasculopathies. Nat Genet 44:838-9
Akhurst, Rosemary J (2010) Taking thalidomide out of rehab. Nat Med 16:370-2
Kang, Jong Seok; Saunier, Elise F; Akhurst, Rosemary J et al. (2008) The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 10:654-64
Harradine, Kelly A; Akhurst, Rosemary J (2006) Mutations of TGFbeta signaling molecules in human disease. Ann Med 38:403-14

Showing the most recent 10 out of 11 publications